Table 2.

Cox-Regression Model of Mortality Among Patients Compared With Matched Controls From the General Population

	Number of Deaths (%)	HR	95% CI
All cause
Chronic patients	1591 (7.4%)
No antipsychotic exposure	199 (9.6%)	6.30	5.46–7.27
Low antipsychotic exposure	261 (6.3%)	4.06	3.58–4.60
Moderate antipsychotic exposure	532 (6.3%)	4.02	3.67–4.41
High antipsychotic exposure	599 (8.8%)	5.68	5.21–6.20
First-episode patients	45 (3.7%)
No antipsychotic exposure	17 (7.3%)	9.90	5.91–16.59
Low antipsychotic exposure	14 (4.3%)	5.39	3.08–9.45
Moderate antipsychotic exposure	6 (1.8%)	2.31	1.01–5.27
High antipsychotic exposure	8 (2.4%)	2.96	1.44–6.08
Specific causes (chronic patients)
Cardiovascular	520 (2.4%)
No antipsychotic exposure	57 (2.7%)	7.59	5.80–9.92
Low antipsychotic exposure	72 (1.8%)	4.68	3.68–5.96
Moderate antipsychotic exposure	178 (2.1%)	5.63	4.79–6.62
High antipsychotic exposure	213 (3.1%)	8.45	7.27–9.83
Neoplasms	262 (1.2%)
No antipsychotic exposure	38 (1.8%)	2.99	2.17–4.13
Low antipsychotic exposure	42 (1.0%)	1.62	1.19–2.20
Moderate antipsychotic exposure	79 (0.9%)	1.48	1.18–1.86
High antipsychotic exposure	103 (1.5%)	2.42	1.98–2.96
Respiratory diseases	175 (0.8%)
No antipsychotic exposure	8 (0.4%)	6.79	3.33–13.87
Low antipsychotic exposure	34 (0.8%)	14.10	9.67–20.58
Moderate antipsychotic exposure	60 (0.7%)	12.10	8.91–16.43
High antipsychotic exposure	73 (1.1%)	18.49	13.87–24.63
Suicide	151 (0.7%)
No antipsychotic exposure	19 (0.9%)	10.92	6.82–17.51
Low antipsychotic exposure	33 (0.8%)	9.27	6.41–13.42
Moderate antipsychotic exposure	60 (0.7%)	8.19	6.13–10.95
High antipsychotic exposure	39 (0.5%)	6.68	4.73–9.43

Note: Since control subjects were matched, no additional adjustment was done for hazard ratios (HRs).